The Industry Standard: Intelligence for the Information Economy

  September 5, 2001
  NEWS & ANALYSIS
   Headlines
   Money & Markets
   Tech & Telecom
   Media & Marketing
   Metrics & Stats
   Policy & Politics
  SEARCH
   
  advanced search
  SERVICES
   Company Index
   Newsletters
   Wireless
  PRINT EDITION
   Read the Magazine

Home > Company Index > Drugs > Biotechnology-Medicine > Immunex Corporation

Immunex Corporation
Nasdaq: IMNX
Change
symbol:
     
 NEWS FROM THE WIRES
Argentine stocks drop on IMF news delay, markets
Aug 21 2001 01:05 PM PDT

RESEARCH ALERT-Deutsche Banc says Immunex on track
Aug 21 2001 01:00 PM PDT

Volkswagen Mexico strike enters fourth day
Aug 21 2001 06:12 AM PDT

U.S. stocks to open unchanged; all eyes on Fed meeting
Aug 21 2001 06:12 AM PDT

Before the Bell-Futures sideways; Agilent off, Immunex up
Aug 21 2001 06:05 AM PDT

More WIRE STORIES about this company

 NEWS FROM THE STANDARD
Late Market Movers: Street Breaks Hex
Mar 23 2001 01:49 PM PST

Back in the Game
Mar 23 2001 09:16 AM PST

After the Bell: Markets Continue to Zigzag
Mar 22 2001 03:50 PM PST

Loudcloud Sets the IPO Tone
Mar 08 2001 11:01 AM PST

 PROFILE
The immune system is a source of wonder -- and profit -- for Immunex. The biotechnology firm develops drugs to treat autoimmune disorders, cancer, and infectious diseases. The company's primary approved products are Enbrel, a leading treatment for rheumatoid arthritis; Leukine, which is used to treat bone marrow transplant patients; and Novantrone, which is used to treat acute nonlymphocytic leukemia and to ease pain associated with prostate cancer. Immunex is also developing drugs that treat asthma, other forms of cancer, and osteoporosis. Pharmaceutical giant American Home Products owns about 40% of Immunex and provides marketing assistance for some of its products.

 COMPETITION
Amgen Inc. (AMGN)
Centocor, Inc. (dossier)

 STOCK ANALYSIS
 View by:
 Day 
 Day 
 Month 
 Month 
 Year 
 Year 
FURTHER ANALYSIS
• Advanced Charting
• Deals

 FINANCIAL OVERVIEW
Fiscal Year-End: December
2000 Sales (mil.): 861.80
1-Yr. Sales Growth: 59.1%
Employees: 1,425
Revenue per employee: $604,771.93

 KEY PEOPLE
• Edward V. Fritzky
    CEO
• David A. Mann
    CFO

 CONTACT INFO
51 University St.
Seattle, WA 98101
US
Phone: 206-587-0430
Fax: 206-587-0606
Online: Web Site

Company Data   News, quotes & more       

Hoovers Online   Hoover's Company Capsule
Copyright © 2001, Hoover's Inc. Austin, Texas.
For changes and updates, contact Hoover's directly.


ADVERTISEMENT
FEATURED LINKS
Home |  Customer Service |  About Us
Australia |  Brazil |  China |  Korea |  Norway |  Poland |  Sweden |  Taiwan

Copyright ©2001 Standard Media International. Privacy Policy
Stock data provided by Stockpoint and its data suppliers. Copyright © 1995-2001